Page results
-
Acute Myeloid Leukaemia (AML) is a form of cancer that develops in your bone marrow and affects your blood cells.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
Your acute myeloid leukaemia (AML) treatment will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Acute lymphoblastic leukaemia (ALL) is a form of cancer that affects the cells in the bone marrow, the soft material inside your bones.
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Bed availability is a “significant” factor in determining whether or not a patient is admitted to a critical care bed after surgery, questioning whether some are getting the care they need, a new study from researchers at UCL and UCLH has found for the first time.
-
This page offers advice to patients who are feeling sick.
-
This page has been written by the Department of Neuroradiology at the National Hospital for Neurology and Neurosurgery (NHNN). Our aim is to provide you with information about endovascular treatments…
-
“No one is invulnerable” – stark messages from patients and staff about the realities of coronavirus
The enormous pressure our staff are under was the focus of a powerful BBC News report about the surge in Covid-19 cases broadcast on Wednesday 6 January.
File results
-
FOI/2022/0428 - Free parking for staff or patients
-
FOI/2022/0431 - Outpatient appointment cancellations
-
FOI/2022/0432 - Bariatric surgery operations
-
FOI/2022/0433 - A&E attendances with effects of heat, light and sunburn
-
FOI/2022/0437 - IT infrastructure systems used at Trust
-
FOI/2022/0443 - Trust spend on lost, stolen or damaged patient property
-
FOI/2022/0448 - Electronic cloud based job evaluation system
-
FOI/2022/0449 - Use of defibrotide for the treatment of Hepatic Veno-occlusive disease
-
FOI/2022/0451 - Patient information leaflets
-
FOI/2022/0454 - Temporary staff waiting list initiative and overtime spend